WebOct 27, 2024 · Bristol Myers Squibb posted third quarter revenues of $11.6 billion, an increase of 10%, driven by Revlimid, Eliquis, Opdivo and our new product portfolio. U.S. … WebOct 29, 2024 · Bristol Myers Squibb’s Q3 2024 adjusted earnings per share (EPS) is expected to be $1.96 per Trefis analysis, compared to $1.92 as per the consensus estimate. Bristol Myers Squibb’s adjusted...
Investors – Cumulus Media
WebOct 26, 2024 · Bristol Myers Squibb’s Q3 2024 adjusted earnings per share is expected to be $1.96 per Trefis analysis, compared to $1.92 as per the consensus estimate. WebNov 16, 2024 · Bristol Myers Squibb to Report Results for Fourth Quarter 2024 on February 4, 2024 December 15, 2024 U.S. Food and Drug Administration Approves Orencia® (abatacept) in Combination with a Calcineurin Inhibitor and Methotrexate for the Prevention of Acute Graft Versus Host Disease (aGvHD)... December 14, 2024 iain macarthur bio
Bristol Myers Squibb Q3 2024 Results Conference Call
WebThis website uses cookies to provide website functionality. With your consent, we may also use third party cookies to analyze your usage of the website. WebOct 28, 2024 · In Q3, the decline accelerated further and BMY generated only $2.4 billion in product sales, a 28% year-over-year decline. It should be noted that this faster decline is … WebQuarterly Results Q3 2024 Earnings Highlights TOTAL NET SALES $11.2B GAAP EPS $0.75* Non-GAAP EPS ** $1.99* YoY 3% increase *Includes the net impact of Acquired IPRD charges and licensing income of $0.02 per share in the third quarter of 2024. molytec stainless thread lubricant sds